Dysmenorrhea Treatment Market Overview
The global dysmenorrhea treatment market is estimated to attain USD 6,312.88 million by the end of 2027, says Market Research Future (MRFR). The report predicts that the market will thrive at a healthy CAGR of over 7.9% during the forecasted era.
Dysmenorrhea, also called menstrual cramps that, affects women. The global dysmenorrhea treatment market has witnessed a massive surge in the growth rate in the last few years. The market’s growth is mainly credited to the growing incidence of dysmenorrhea among adolescent girls worldwide. Furthermore, factors such as rising cases of menstrual cramps due to genetic disorders, increasing female population, and growing menstrual health awareness are also likely to boost the market’s growth over the forecasted era. On the other hand, the high availability of alternative products and concerns about the side effects are likely to challenge the market’s growth.
Request Free Sample Copy at:https://www.marketresearchfuture.com/sample_request/727
Dysmenorrhea Treatment Market Segmentation
The global market for dysmenorrhea treatment has been fragmented into various segments based on product type, end-user, treatment type, and region.
Based on product type, the global market for dysmenorrhea treatment is divided into secondary dysmenorrhea and primary dysmenorrhea.
The dysmenorrhea treatment market is split into surgery, hormonal therapy, pain relievers, and others based on treatment type.
Based on end-user, the global market for dysmenorrhea treatment is divided into research centers, hospitals & clinics, and others.
Dysmenorrhea Treatment Market Regional Outlook
The global dysmenorrhea treatment market is analyzed across five major regions, including the Middle East & Africa, Asia-Pacific, the Americas, and Europe.
The MRFR report suggests that the American region will likely secure the top position in the global market for dysmenorrhea treatment over the forecasted era. The regional market’s growth is attributed mainly to the increasing number of patients suffering from menstrual disorders.
The European regional market for dysmenorrhea treatment is likely to hold the second position in the global dysmenorrhea treatment market over the coming years. The increasing number of clinical trials concentrated on relieving pain associated with dysmenorrhea is the primary aspect causing an upsurge in the regional market’s growth.
The dysmenorrhea treatment market for the Asia-Pacific region is anticipated to be the fastest-growing market worldwide. The regional market’s growth is attributed to the rise in the level of awareness about the condition and increasing population across the region.
The Middle East & African regional market for dysmenorrhea treatment is likely to register the least growth over the assessment era. The growth of the market is mainly credited to the severity of outcomes of undiagnosed cases and growing awareness created by research studies.
Dysmenorrhea Treatment Market Competitive Analysis
The global market for dysmenorrhea treatment is well-known for the presence of a wide number of players spread worldwide. The players across the global market are serving to growth in generics and CROs, government investment in academics and life sciences, and technological advancements. The growing cases of menstrual cramps due to genetic disorders and the growing prevalence of dysmenorrhea among adolescent girls are likely to intensify the competition across the global market. The global dysmenorrhea treatment market has prominent players such as Bayer AG (Germany), GlaxoSmithKline PLC (U.K.), Viatris Inc. (U.S.), Reckitt Benckiser Group plc. (U.K.), Novartis AG (Switzerland), Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson (U.S.), Sanofi S.A. (France), Pfizer, Inc. (U.S.), Focus Consumer Healthcare, LLC (U.S.), and several others.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/dysmenorrhea-treatment-market-727
- In March 2022, a biopharmaceutical company developing and commercializing novel therapies for women’s health, ObsEva SA, announced extra efficiency results from the Phase 3 EDELWEISS 3 trial of an oral GnRH antagonist, linzagolix, in women with moderate-to-severe endometriosis-associated pain (EAP). The conclusions are based on the positive topline results revealed in January 2022.
- October 2021- A research study by MysteryVibediscovered that their device, Crescendo, which is developed to deal with genito-pelvic pain disorder, can also be instrumental in reducing period pain.
Browse Related Reports at:
Surgical Robots Market Research Report – Global Forecast till 2027
Intraoperative Neurophysiological Monitoring Market Research Report – Global Forecast to 2027
Biosensor Market Research Report – Global Forecast till 2027
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071